Back to search

Article

A phase II study on the efficacy of regorafenib in treating patients with c-KIT-mutated metastatic malignant melanoma that progressed after previous treatment (KCSG-UN-14-13)

2023-05-11

Abstract excerpt

<h4>Background: </h4> c -KIT mutations are found in approximately 15% of the patients with malignant melanoma; agents such as imatinib have previously shown high response rates. Regorafenib, an oral multikinase inhibitor, acts against wild-type and mutant KIT. This multi-institutional phase II single-arm study aimed to evaluate the efficacy of regorafenib against metastatic malignant melanoma harboring the c- KIT...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
e67a5604-744f-52d8-a510-57847b2629b7
DOI
10.21203/rs.3.rs-2906574/v1
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
A phase II study on the efficacy of regorafenib in treating patients with c-KIT-mutated metastatic malignant melanoma that progressed after previous treatment (KCSG-UN-14-13)DOI 10.21203/rs.3.rs-2906574/v1
A phase II study on the efficacy of regorafenib in treating patients with c-KIT-mutated metastatic malignant melanoma that progressed after previous treatment (KCSG-UN-14-13).Semantic proximity
Efficacy and safety of regorafenib in patients with advanced pretreated melanoma: results of the RegoMel phase II clinical trial.Semantic proximity
Functional and sensitivity profiling of the <i>KIT</i> Mutation Landscape in MelanomaSemantic proximity
Long-term follow-up results of the multicenter phase II trial of regorafenib in patients with metastatic and/or unresectable GI stromal tumor after failure of standard tyrosine kinase inhibitor therapy.Semantic proximity
Imatinib in c-KIT-mutated metastatic solid tumors: A multicenter trial of Korean Cancer Study Group (UN18-05 Trial).Semantic proximity
Final analysis of a post-marketing surveillance study of dabrafenib and trametinib combination therapy in Japanese patients with unresectable malignant melanoma with BRAF V600 mutation.Semantic proximity
c-Kit inhibitors for unresectable or metastatic mucosal, acral or chronically sun-damaged melanoma: a systematic review and one-arm meta-analysis.Semantic proximity
A real-world study of adjuvant anti-PD -1 immunotherapy on stage III melanoma with BRAF, NRAS, and KIT mutations.Semantic proximity
Deciphering resistance mechanisms in cancer: final report of MATCH-R study with a focus on molecular drivers and PDX development.Semantic proximity
Comparative analysis of adjuvant therapy for stage III BRAF-mut melanoma: A real-world retrospective study from single center in China.Semantic proximity
Continuous Infusion of Endostar Combined with Chemotherapy in Patients with Advanced or Recurrent Mucosal Melanoma: A Real-World Cohort StudySemantic proximity
Efficacy and safety of nilotinib in patients with KIT-mutated metastatic or inoperable melanoma: final results from the global, single-arm, phase II TEAM trial.Semantic proximity
Select a neighboring publication to make it the new centre.